Introduction: Neuroendocrine tumors (NET) express diffe rent types of somatostatin receptors (SSTRs) that bind to syn thetic analogs with variable affinity. It is important to know the expression profile of SSTRs to predict biological effect of somatostatin analogues. We studied SSTR2 and SSTR5 expre ssion by immunohistochemistry (IHC) to assess the dominant sub type in NETs and correlate the expression with histological prognostic parameters.
INTRoDuCTIoN
Neuroendocrine tumors (NET) are heterogeneous group of neoplasms that arise primarily in gastrointestinal tract (GIT), pancreas and lung. 1 Ninety percent of these tumors are nonfunctional, that is, they do not produce biologically active peptides but are diagnosed late because of their mass effect. 2 A common feature of all NETs is expression of different types of somatostatin receptors (SSTRs) which are seen in approximately 80 to 90% of gastroenteropancreatic neuroendocrine tumors (GEP-NET). 2, 3 The expression of different types of SSTRs varies between NETs of different tissues and also in the NET of same tissue. 4 These SSTRs bind to natural and synthetic somatostatin analogs with variable affinity having the high affinity for SSTR2 and SSTR5 and low for SSTR3.
5,6
The dominant receptor subtype in majority of NETs is SSTR2 followed by SSTR5, SSTR3 and SSTR1. Somatostatin receptor 4 is the least expressed receptor. 1, 3, 7 There are several methods to detect SSTRs inclu ding quantification of receptor mRNA, in situ hybridization, immunohistochemistry for receptor proteins and somatostatin receptor scintigraphy. Of these, scintigraphy remains the gold standard however false positive scintigraphy may result from areas of necrosis and inflammation within the tumor. 8 Immunohistochemistry has certain advantages over other methods as it is a direct visualization of the protein in cell with detection of cell type as well as the receptor type because of variable affinity and expression pattern of these receptors. This is important because SSTRs are not only expressed in NETs but also in other tumors like colorectal cancer, breast cancer, meningioma, neuroblastoma, etc. 9 It is also expressed in non-neoplastic cells like endothelial cells, lymphocytes, fibroblasts, macrophages, etc.
10,11
Synthetic somatostatin analogs have a longer halflife of 2 hours in contrast to 1 to 3 minutes of the natural somatostatin and therefore, are a choice of treatment in functional NETs. 12 Because of different expression patterns of SSTRs and a variable affinity of synthetic wjOes somatostatin analogs, it is important to know the expression profile of SSTRs. The present study was designed with an aim to evaluate the dominant expression patterns of commonly expressed SSTRs having high affinity for synthetic somatostatin analogs in NETs of different anatomic sites. 
MATeRIAlS AND MeThoDS
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STATISTICS
Somatostatin receptor 2 and SSTR5 expression were correlated with histological parameters using Chi-square test (SPSS version 15).
ReSulTS
A total of consecutive 53 cases were evaluated. The bulk of cases were from surgical gastroenterology speciality accounting for 31 cases followed by surgical endocrinology speciality with 16 cases whereas five cases of lung NET and one case of urinary bladder NET were from departments of pulmonary medicine and urology res pectively. Age ranged from 16 to 81 years with mean of 50.7 years and median of 52 years. Male to female ratio was 1.2:1. Forty-four cases were resected specimens and nine cases were endoscopic or needle biopsies. Nine (16.9%) cases (7 pancreatic, 1 thymic and 1 duodenal) were functional tumors. All pancreatic tumors were insulinomas whereas one duodenal tumor was a gastrinoma and one thymic tumor had Cushing syndrome. Twenty-four of 53 cases were from GIT, 19 from pancreas and 10 cases of other miscellaneous sites ( Table 2) . Eleven cases (20.7%) were negative for both SSTR subtypes. All the positive cases showed SSTR staining in at least 30% or more tumor cells. Overall cytoplasmic pattern of expression was more common than cytoplasmic and membranous staining and SSTR5 showed a higher expression compared to SSTR2 in all organ systems (Table 3) . Somatostatin receptor 2 was expressed more in low grade tumors as classified by mitotic count and Ki-67 labeling index. Both SSTR2 and SSTR5 showed less lymph node metastasis compared to SSTR negative NETs. Somatostatin receptor 5 was expressed more in small size tumors (< 2 cm, p = 0.02) (Table 4) .
Necrosis, anatomic location and tumor stage did not show any correlation with SSTR expression.
DISCuSSIoN
Nearly 90% of GEP-NETs are nonfunctional tumors where surgical excision is the initial and curative approach.
wjOes
However about 10% of tumors are functional and produce systemic symptoms affecting the quality of life. In these functioning tumors and metastatic or unresectable tumors, the approach is to improve the quality of life by giving synthetic somatostatin analogs. The synthetic somatostatin analogs which have a longer half-life than naturally occurring somatostatins act through different SSTRs present on the cell surface of neuroendocrine and other non-neuroendocrine tumors and act by inhibiting the release of different endocrine hormones as well as by anti-proliferative affect which is helpful even in nonfunctioning tumors. The anti-proliferative effect mediates directly by cell cycle arrest and inducing apoptosis and indirectly by decreasing growth factors, inhibiting angiogenesis and immunomodulation. 1, 14 The natural somatostatin binds with all SSTR subtypes but the synthetic analogs have variable affinity with different receptor types. Most of the synthetic analogs act through SSTR2 and SSTR5 whereas the newer panreceptor agonist, pasireotide, binds SSTR5, SSTR3 and SSTR1 with much higher affinity than SSTR2.
14-16
In the present study overall SSTR expression was seen in 79.2% of NETs from different anatomic sites with SSTR5 expression in 73.6% and SSTR2 expression in 56.6% tumors. We found combined cytoplasmic and membranous pattern of positivity in both the receptor subtypes. There are few reports on immunohistochemical expression of SSTRs in NETs. Most of the studies have shown a high SSTR2 expression of more than 80%.
17,18
Papotti et al studied three receptors-SSTR 2, 3 and 5 and found an overall SSTR expression of 75% in 81 cases. They found nearly equal expression of SSTR2 (68.2%) and SSTR5 (63.6%) and lower expression for SSTR3 (36.4%). 3 Takei et al studied both SSTR2 and SSTR5 and found 100% positivity for SSTR2 and 94.5% for SSTR5. 19 Pisarek et al studied all six somatostatin receptors (SSTR1, 2A, 2B, 3, 4 and 5) and found SSTR2 (47.1%) expression less than SSTR5 (58.8%). 20 Similarly Nasir et al also found SSTR5
(91%) to show higher expression than SSTR2 (81%) which they explained was because of patients receiving synthetic somatostatin analog therapy at the time of surgery and SSTRs are internalized into the cytoplasm with synthetic analog therapy. 21 In the present study also SSTR5 (73.5%) had higher expression than SSTR2 (56.6%) and none of the patients were on synthetic analog therapy during surgery. Reubi et al studied SSTRs by receptor autoradiography technique and showed higher level of expression in well differentiated tumors than poorly differentiated tumors. 22 Volante et al showed 79% expression of STTRs in well differentiated tumors and 44% in poorly diffe rentiated NETs. 11 Similarly in the present study either one or both SSTRs were seen in 78.2% of well differentiated NETs and 75% of poorly differentiated NETs. Both receptor subtypes was negative in 21.8% of well differentiated and 25% of poorly differentiated tumors. Because of different mechanism of effect, variable affinity to the synthetic analogs and also variable expression on different tumor subtypes of the different SSTRs, it is beneficial to have knowledge of the receptor subtype expression on particular tumor before starting patient on synthetic analogs. Although somatostatin scintigraphy is the gold standard, immunohistochemistry has the advantage of in situ localization with cell type and receptor type identification and also avoids false positivity.
CoNCluSIoN
The present study showed SSTR5 to be the dominant subtype expressed in NETs of different anatomic sites. The expression of SSTR2 was more in low grade tumors and SSTR5 was commonly expressed in small sized NETs (< 2 cm). Somatostatin receptors apart from being useful in functioning tumors may be useful in nonfunctioning and non-resectable tumors because of their antimitotic activity.
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